Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

NCT01420679 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T-cell Lymphoma

Interventions

DRUG: Pralatrexate Injection

Sponsor

Spectrum Pharmaceuticals, Inc